Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide and Temozolomide in Pediatric Brain Tumors or Neuroblastoma
NCT00098865Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Sep 2002
- Primary completion
- Jun 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of thalidomide in brain tumor and neuroblastoma, sponsored by Dana-Farber Cancer Institute. Primary endpoint: Therapy Completion Rate at 6 months. Started Sep 2002; status: completed.
02
Drugs
thalidomide
03
Conditions
brain tumorneuroblastoma
Beyond the preview
Go deeper on NCT00098865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00098865.